Insys Therapeutics (INSY) Tops Q3 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oppenheimer Downgrades INSYS Therapeutics (INSY) to Perform
November 12, 2014 8:58 AM ESTOppenheimer downgraded INSYS Therapeutics (NASDAQ: INSY) from Outperform to Perform and removed its price target (prior $40.00).
For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.
Shares of INSYS Therapeutics closed at $41.52 yesterday.
... More